State Street
CLYM

State Street’s Climb Bio CLYM Stock Holding History

State Street’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$904K Buy
132,000
+3,100
+2% +$17.9K ﹤0.01% 3512
2025
Q4 		$516K Buy
128,900
+25,800
+25% +$62K ﹤0.01% 3667
2025
Q3 		$207K Hold
103,100
– – ﹤0.01% 3904
2025
Q2 		$128K Sell
103,100
-275,436
-73% -$343K ﹤0.01% 3934
2025
Q1 		$462K Hold
378,536
– – ﹤0.01% 3612
2024
Q4 		$681K Buy
378,536
+63,500
+20% +$230K ﹤0.01% 3560
2024
Q3 		$1.6M Buy
315,036
+256,029
+434% +$1.81M ﹤0.01% 3392
2024
Q2 		$420K Buy
59,007
+37,307
+172% +$248K ﹤0.01% 3596
2024
Q1 		$59.5K Hold
21,700
– – ﹤0.01% 4128
2023
Q4 		$58.2K Hold
21,700
– – ﹤0.01% 4169
2023
Q3 		$57.3K Buy
21,700
+1,900
+10% +$5.18K ﹤0.01% 4252
2023
Q2 		$55.4K Hold
19,800
– – ﹤0.01% 4393
2023
Q1 		$57.4K Hold
19,800
– – ﹤0.01% 4471
2022
Q4 		$70.9K Hold
19,800
– – ﹤0.01% 4466
2022
Q3 		$64K Hold
19,800
– – ﹤0.01% 4602
2022
Q2 		$60K Sell
19,800
-75,270
-79% -$356K ﹤0.01% 4688
2022
Q1 		$798K Buy
95,070
+1,991
+2% +$18.6K ﹤0.01% 3880
2021
Q4 		$974K Buy
93,079
+6,978
+8% +$104K ﹤0.01% 3820
2021
Q3 		$1.55M Buy
+86,101
New +$1.78M ﹤0.01% 3682

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

State Street's CLYM Position: Q1 2026 in Review

State Street increased its Climb Bio (CLYM) stake by 2.4% in Q1 2026, buying an estimated $17.9K and bringing the position to 132,000 shares worth $904K. The position accounts for ﹤0.01% of the portfolio, ranked #3512.

State Street first reported a position in CLYM in Q3 2021 and has held it in 19 quarters since. The position peaked at $1.6M in Q3 2024. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • State Street held 132,000 shares of Climb Bio worth $904K as of Q1 2026.
  • State Street bought 3,100 Climb Bio shares in Q1 2026, an estimated $17.9K.
  • Climb Bio made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3512 holding.
  • State Street first reported a position in Climb Bio in Q3 2021 and has held it in 19 quarters since.
  • State Street's Climb Bio position peaked at $1.6M in Q3 2024.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.